Health and Healthcare
Short Interest Rises Across the Board in Major Biotechs
Published:
Last Updated:
The short interest data are out for the February 12 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise slightly to 10.63 million shares from the previous level of 10.41 million. Shares closed most recently at $147.11, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 3.37 million from the previous level of 2.76 million. Shares closed Wednesday at $257.22, within a 52-week range of $242.07 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 11.74 million shares from the previous 10.50 million. Shares of Celgene closed most recently at $102.08, in a 52-week range of $92.98 to $140.72.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest jump to 39.79 million shares from 21.37 million in the previous period. Shares closed Wednesday at $89.36, in a 52-week trading range of $81.89 to $123.37.
MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 130.25 million shares. The previous reading was 124.41 million. Shares closed most recently at $1.00, in a 52-week trading range of $0.64 to $7.32.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 5.66 million, compared to the previous level of 5.47 million. Shares closed most recently at $141.97, in a 52-week range of $130.51 to $208.88.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
